Is Neuland Laboratories a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Neuland Laboratories Ltd is a average quality company .

Is Neuland Laboratories undervalued or overvalued?

The key valuation ratios of Neuland Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Neuland Laboratories share price return in the past 10 years?

Neuland Laboratories Ltd share price has appreciated 39.2% annually (CAGR) over the past ten years.

Is Neuland Laboratories a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Neuland Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Neuland Laboratories Ltd - Stock Valuation and Financial Performance

Name: Neuland Laboratories
Brand: Neuland Laboratories

BSE: 524558 | NSE: NEULANDLAB | Pharmaceuticals & Drugs | Small Cap

Place order

Neuland Laboratories Share Price

₹11,658.05 -128.80 -1.09%
as on 08-Jul'25 12:46

Neuland Laboratories Ltd - Stock Valuation and Financial Performance

BSE: 524558 | NSE: NEULANDLAB | Pharmaceuticals & Drugs | Small Cap

Place order

Neuland Laboratories Share Price

₹11,658.05 -128.80 -1.09%
as on 08-Jul'25 12:46

10 Year X-Ray of Neuland Laboratories:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	18.5%	15.9%	4%	4%	7.8%	12.8%	9.4%	21%	33.6%	23.5%	-
Value Creation Index ⓘ	0.3	0.1	-0.7	-0.7	-0.4	-0.1	-0.3	0.5	1.5	0.7	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	510	579	527	667	763	937	951	1,191	1,559	1,477	1,477
Sales YoY Gr.	-	13.5%	-8.9%	26.4%	14.4%	22.8%	1.5%	25.3%	30.8%	-5.2%	-
Adj EPS ⓘ	29.3	53.1	13.8	15.5	13.1	56.8	50.6	131.3	233.6	159.9	202.2
YoY Gr.	-	81%	-73.9%	11.9%	-15.5%	334%	-10.9%	159.7%	77.9%	-31.5%	-
BVPS (₹) ⓘ	206.3	260	273.5	541.5	549.2	608.7	650.6	769.7	994.3	1,182.3	1,182.3
Adj Net Profit ⓘ	26.1	47.2	12.3	19.9	16.8	72.8	64.9	168	300	205	259
Cash Flow from Ops. ⓘ	44.7	38.9	11.5	69.6	56.6	189	60.4	239	260	317	-
Debt/CF from Ops. ⓘ	4.1	4.9	27.7	3.3	4.6	0.9	3.8	0.5	0.3	0.4	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	12.5%	14.1%	15.8%	-5.2%
Adj EPS ⓘ	20.7%	65%	46.8%	-31.5%
BVPSⓘ	21.4%	16.6%	22%	18.9%
Share Price	39.2%	85.5%	104.4%	52.2%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	15.1	13	2.2	3.2	2.4	9.8	8	18.5	26.5	14.7	17.1
Op. Profit Mgn % ⓘ	15.7	18.5	9.6	9.5	13.5	15.9	15.2	23.7	29.7	22.3	21.8
Net Profit Mgn % ⓘ	5.1	8.2	2.3	3	2.2	7.8	6.8	14.1	19.2	13.9	17.6
Debt to Equity ⓘ	1	0.8	1.3	0.3	0.4	0.2	0.3	0.1	0.1	0.1	0.1
Working Cap Days ⓘ	233	220	284	242	225	207	218	198	183	204	147
Cash Conv. Cycle ⓘ	87	106	152	121	116	106	123	115	98	100	84

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 15.80%

Net Profit is growing at healthy rate in last 3 years 46.80%

Return on Equity has declined versus last 3 years average to 17.10%

Sales growth is not so good in last 4 quarters at -4.47%

Latest Financials - Neuland Laboratories Ltd.

	Standalone	Consolidated
TTM EPS (₹)	202.2	202.7
TTM Sales (₹ Cr.)	1,477	1,477
BVPS (₹.) ⓘ	1,182.3	1,187.8
Reserves (₹ Cr.) ⓘ	1,504	1,511
P/BV ⓘ	9.97	9.92
PE ⓘ	58.29	58.14

From the Market
52 Week Low / High (₹)	7575.00 / 18089.55
All Time Low / High (₹)	14.26 / 18089.55
Market Cap (₹ Cr.)	15,122
Equity (₹ Cr.)	12.8
Face Value (₹)	10
Industry PE ⓘ	41.9

Management X-Ray of Neuland Laboratories:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Neuland Laboratories

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

No data found!

Key Ratios of Neuland Laboratories

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	510	579	527	667	763	937	951	1,191	1,559	1,477
Operating Expenses ⓘ	430	473	477	609	661	790	809	920	1,097	1,155
Manufacturing Costs	62	71	81	77	98	116	131	136	157	163
Material Costs	253	263	238	366	380	438	422	478	577	588
Employee Cost	60	85	96	104	118	144	176	195	249	261
Other Costs ⓘ	55	55	62	61	65	92	80	111	114	143
Operating Profit ⓘ	80	106	50	58	101	146	142	271	462	322
Operating Profit Margin (%)	15.7%	18.3%	9.5%	8.7%	13.3%	15.6%	15.0%	22.8%	29.6%	21.8%
Other Income ⓘ	2	1	5	3	4	16	2	10	13	21
Interest ⓘ	24	21	19	16	22	18	13	13	14	8
Depreciation ⓘ	16	19	22	26	31	40	49	53	60	66
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	76
Profit Before Tax ⓘ	41	67	14	20	52	105	82	215	401	345
Tax ⓘ	15	20	2	4	37	25	18	52	101	86
Profit After Tax	26	46	12	16	16	80	64	163	300	259
PAT Margin (%)	5.2%	8.0%	2.2%	2.4%	2.1%	8.6%	6.7%	13.7%	19.2%	17.6%
Adjusted EPS (₹)	29.7	52.2	13.3	12.6	12.4	62.6	49.5	127.1	233.5	202.2
Dividend Payout Ratio (%)	7%	0%	0%	10%	16%	8%	10%	8%	6%	6%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund	184	232	244	696	706	782	836	988	1,277	1,518
Share Capital ⓘ	9	9	9	13	13	13	13	13	13	13
Reserves ⓘ	175	223	235	683	693	769	823	975	1,264	1,505
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	169	181	303	210	246	145	196	85	45	91
Long Term Debt	45	30	103	61	77	88	104	74	45	91
Short Term Debt	124	151	199	149	168	57	92	11	0	0
Trade Payables	86	89	129	124	120	157	123	178	199	261
Others Liabilities ⓘ	84	383	395	101	159	240	227	328	311	309
Total Liabilities ⓘ	523	885	1,071	1,130	1,230	1,324	1,382	1,579	1,831	2,178
Fixed Assets
Gross Block	292	455	483	575	714	826	913	953	1,070	1,238
Accumulated Depreciation	153	19	38	64	92	130	166	215	265	283
Net Fixed Assetsⓘ	139	436	445	512	623	697	748	738	805	955
CWIP ⓘ	40	20	126	104	24	17	20	41	46	48
Investmentsⓘ	8	8	8	8	8	7	4	1	1	109
Inventories	127	135	175	193	220	248	265	279	350	386
Trade Receivables	119	181	194	164	190	218	234	362	374	316
Cash Equivalents	9	12	17	37	46	18	19	59	115	257
Others Assetsⓘ	82	93	106	112	120	119	91	100	140	108
Total Assets ⓘ	523	885	1,071	1,130	1,230	1,324	1,382	1,579	1,831	2,178

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ	45	39	12	70	57	189	60	239	260	317
PBT ⓘ	41	67	14	20	52	105	82	215	401	345
Adjustment ⓘ	34	44	40	39	58	40	66	78	62	-12
Changes in Working Capital ⓘ	-19	-55	-39	16	-49	49	-67	-11	-91	59
Tax Paid ⓘ	-12	-16	-3	-5	-5	-5	-21	-44	-112	-75
Cash Flow From Investing Activity ⓘ	-20	-42	-116	-77	-49	-84	-96	-61	-150	-298
Capex	-19	-41	-133	-63	-48	-105	-98	-65	-144	-111
Net Investments	-1	-1	15	-16	-6	19	2	2	2	-99
Others ⓘ	0	0	1	1	5	2	1	2	-8	-88
Cash Flow From Financing Activityⓘ	-24	0	105	12	-5	-114	38	-136	-69	25
Net Proceeds from Shares ⓘ	0	0	0	125	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	16	-5	79	-39	9	22	23	-33	-28	55
Interest Paid ⓘ	-16	-21	-22	-25	-24	-18	-14	-13	-14	-8
Dividend Paid ⓘ	-2	-1	0	0	-5	-3	-4	-6	-13	-18
Others ⓘ	-22	27	48	-49	14	-115	32	-84	-14	-4
Net Cash Flow ⓘ	1	-3	0	4	2	-9	3	41	41	44

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	15.44	22.39	4.98	3.44	2.27	10.81	7.86	17.9	26.48	18.58
ROCE (%)	18.46	15.94	4.04	3.95	7.84	12.83	9.44	20.99	33.62	23.49
Asset Turnover Ratio	1	0.83	0.54	0.61	0.65	0.73	0.7	0.8	0.91	0.74
PAT to CFO Conversion(x)	1.73	0.85	1	4.38	3.56	2.36	0.94	1.47	0.87	1.22
Working Capital Days
Receivable Days	87	93	129	98	85	79	87	91	86	85
Inventory Days	85	81	107	101	99	91	98	83	74	91
Payable Days	143	121	167	126	117	115	121	115	119	143

Neuland Laboratories Ltd Stock News

Neuland Laboratories Ltd FAQs

What is the share price of Neuland Laboratories?

Company share prices are keep on changing according to the market conditions. The closing price of Neuland Laboratories on 08-Jul-2025 12:46 is ₹11,658.1.

What is the market cap of Neuland Laboratories?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 08-Jul-2025 12:46 the market cap of Neuland Laboratories stood at ₹15,122.4.

What is the P/E ratio of Neuland Laboratories?

The latest P/E ratio of Neuland Laboratories as of 08-Jul-2025 12:46 is 58.29.

What is the P/B ratio of Neuland Laboratories?

The latest P/B ratio of Neuland Laboratories as of 08-Jul-2025 12:46 is 9.97.

What is the 52-week high and low of Neuland Laboratories?

The 52-week high of Neuland Laboratories is ₹18,089.6 and the 52-week low is ₹7,575.

What is the TTM revenue of Neuland Laboratories?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Neuland Laboratories is ₹1,477 ( Cr.) .

About Neuland Laboratories Ltd

Named after Father Nieuwland of Notre dame, Neuland Laboratories was incorporated in 1984 by Dr. D. R. Rao for the manufacture of Salbutamol Sulphate, with mere 40 employees.

It has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.

Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery. Neuland is a quality conscious, research driven, reliable source of active pharmaceutical ingredients.

Operating from India for over two decades, Neuland is the preferred source for the Pharmaceutical Industry across the globe, with strengths in Research based Chemistry and Manufacturing.

The Company has started its commercial production of Salbutamol Sulphate in the year 1986. It has since grown to become one of the most reliable API source for Pharma Industry with addition of more products in course of years.Today the company with a total employee strength of 1000+ is the preferred supplier of APIs with unmatched quality and timely delivery.

Neuland has two world-class API manufacturing facilities close to the city of Hyderabad, capable in handling complex and hazardous reactions. Safety aspects have been given utmost significance may it be plant installation, equipment, systems and personnel to ensure smooth productivity. Dedicated team of manufacturing with incorporation of latest production techniques guarantees delivery of latest intermediate and product to our customers across the globe.

Product range of the company includes:

Anti -Asthmatics
Fluoroquinolones
Cardiovascular
CNS
Corticosteroids
Anti-Ulcerant
Anti-Fungal
Anti-Parkinsons
Anti-Alzheimers

Achievements/ recognition:

Received a string of regulatory approvals from USFDA & EDQM for its major products (e.g., Ciprofloxacin HCl, Salbutamol Sulphate) USFDA systems inspection for its pashamylaram Facility (Unit-II) in the year 1999
USFDA systems inspection for its Bonthapally (Unit-I) bringing both facilities under full cGMP compliance in 2004
Received cGMP clearance for both facilities from TGA, Australia in 2004.
Certificate of suitability for product itraconazole in 2006.

SEBI Registered: Investment Adviser - INA000013323 RIA Details

Warning: Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Disclaimer: Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provides any assurance of returns to investors.

Compliance Officer:

Name: Shrikant Jagtap

Email: shrikant.jagtap@moneyworks4me.com

Mobile No: +91 97638 00745

Grievance Officer:

Name: Mukta Vaze

Email: mukta.vaze@moneyworks4me.com

Mobile No:+91 98609 19463

Principal Officer:

Name: Atharva Bhide

Email: atharva.bhide@moneyworks4me.com

Mobile No:+91 91758 99463

SEBI regional/local office address-

Plot No. C 4-A , G Block, Near Bank of India, Bandra Kurla Complex, Bandra East, Mumbai, Maharashtra 400051

Address:

The Alchemists Ark Pvt. Ltd., B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Data provided by Accord Fintech Pvt. Ltd.

Please wait your portfolio is updating...

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity - May 16, 2019 - Perpetual
BASL Membership ID:	BASL1187
Address	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Neuland Laboratories Ltd - Stock Valuation and Financial Performance

Neuland Laboratories Share Price

Neuland Laboratories Ltd - Stock Valuation and Financial Performance

Neuland Laboratories Share Price

DeciZen - make an informed investing decision on Neuland Laboratories Share

Overall Rating ⓘ

1. Quality

2. Valuation ⓘ

3. Price Trend

Neuland Laboratories stock performance -

Is Neuland Laboratories Ltd an attractive stock to invest in?

1. Is Neuland Laboratories Ltd a good quality company?

2. Is Neuland Laboratories Ltd undervalued or overvalued?

3. Is Neuland Laboratories Ltd a good buy now?

10 Year X-Ray of Neuland Laboratories: Share

Analysis of Financial Track Record

Value Creation ⓘ

Growth Parameters ⓘ

CAGR ⓘ

Key Financial Parameters ⓘ

Recent Performance Summary

Latest Financials - Neuland Laboratories Ltd.

Management X-Ray of Neuland Laboratories: Share

Shareholding Pattern

Promoter's Holding & Share Pledging